News For SQNM;HITK;DSCI;HTWR;IMGN;MDAS;CRVL;CCRN;AMED;AEZS From The Last 14 Days
|November 30, 2015|
|09:15 EDT||AEZS||On The Fly: Pre-market Movers |
HIGHER: Anavex Life Sciences (AVXL), up 20.5% after 3-71 data published in Neurodegenerative Diseases... Oramed Pharmaceuticals (ORMP), up 16.7% after signing up to $50M licensing and investment agreements for insulin in China... Horizon Pharma (HZNP), up 3.8% after receiving EC approval for Ravicti... Fitbit (FIT), up 4.2% after being upgraded to Overweight from Equal Weight at Barclays... Sarepta Therapeutics (SRPT), up 1.6% following a positive mention by Barron's. LOWER: Cyclacel Pharmaceuticals (CYCC) and AEterna Zentaris (AEZS), down 24.5% and 13.6%, respectively, following a Tweet by KaloBios (KBIO) CEO Martin Shkreli... Supercom (SPBC), down 21.6% after reporting preliminary third quarter revenue... Macrocure (MCUR), down 11.5% after announcing that the company's CFO and Chief Medical Officer are stepping down... lululemon (LULU), down 4.4% after being downgraded to Underperform from Market Perform at FBR Capital... Office Depot (ODP), down 2.8% after the NY Post reported that regulators are preparing to block Staples' (SPLS) proposed acquisition of Office Depot... SouFun (SFUN), down 2% after being downgraded to Neutral from Buy at Goldman.
|08:59 EDT||AEZS||Cyclacel Pharmaceuticals, Aeterna Zentaris 'worthless,' says Shkreli|
Martin Shkreli, the CEO KaloBios (KBIO) and Turing Pharma, said in a tweet that Cyclacel Pharmaceuticals (CYCC) and Aeterna Zentaris (AEZS) shares are "worthless." Shares of both stocks are indicated lower this morning following Shkreli's Twitter post. Reference Link
|November 25, 2015|
|13:11 EDT||AEZS||Aeterna Zentaris CEO responds to recent developments, says fundamentals 'strong'|
Aeterna Zentaris chairman and CEO David Dodd released a statement seeking to provide clarity on what he called recent "corporate developments." Dodd said, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen after a panel of U.S. and EU endocrinology experts advised us to continue to seek approval for the compound because of their confidence in its efficacy and because there currently is no FDA-approved diagnostic test for adult growth hormone deficiency. That Phase 3 study recently enrolled its first patient, keeping us on track to conclude it by the end of 2016... We continue discussions with others about adding to our portfolio of promoted products and about the commercial rights to and development of Zoptrex in markets outside the United States."
|10:00 EDT||IMGN||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: Actelion (ALIOY) upgraded to Neutral from Sell at Citi... Alliance Data (ADS) assumed with an Overweight from Neutral at Piper Jaffray... BG Group (BRGYY) upgraded to Outperform from Sector Perform at RBC Capital... Cubic (CUB) upgraded to Buy from Hold at Benchmark... Frontline (FRO) upgraded to Neutral from Underperform at Credit Suisse... Hormel Foods (HRL) upgraded to Overweight at Stephens... ImmunoGen (IMGN) assumed with a Buy from Hold at Jefferies... Metro (MTTRY) upgraded to Buy from Hold at Jefferies... Palo Alto (PANW) upgraded to Buy from Hold at Argus... Pfizer (PFE) upgraded to Neutral from Reduce at SunTrust... Tech Data (TECD) upgraded to Market Perform from Underperform at Raymond James.
|06:26 EDT||IMGN||ImmunoGen assumed with a Buy from Hold at Jefferies|
Jefferies analyst Biren Amin upgraded ImmunoGen to Buy after assuming coverage of the name. Mirvetuximab has shown "robust activity" in patients with ovarian cancer that are highly expressing the folate receptor, and data from an additional 40 patients in Q2 of 2016 could be the next catalyst for the stock, Amin tells investors in a research note. He doubled his price target for ImmunoGen shares to $16 from $8.
|November 24, 2015|
|12:59 EDT||AEZS||GEO Investing says Aeterna Zentaris rally 'totally unwarranted'|
GEO Investing tweeted, "We believe $AEZS pump is totally unwarranted and that stock will quickly follow if $KBIO sells off."
|11:30 EDT||AEZS||Aeterna Zentaris says no corporate developments to account for stock movement|
Aeterna Zentaris, at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release there are no corporate developments that would cause the recent movements in the company's share price.
|November 20, 2015|
|08:32 EDT||MDAS||MedAssets extends strategic partnership with HealthTechS3 |
MedAssets announced an extension of its long-standing strategic partnership with HealthTechS3, or HTS3, a Brentwood, Tenn.-based provider of financial services, executive/physician recruitment, consulting/management services and supply chain solutions to critical access and acute care hospitals in rural areas and smaller communities across the United States. The agreement continues a successful 20-year participation in HTS3's Business Partnership Program, through which HTS3 customers can access MedAssets' supply chain and capital and construction solutions to reduce the total cost of care. Through this ongoing relationship, MedAssets offers the pricing advantages of its contracted supplies, purchased services and capital equipment, as well as tools and field expertise to gain greater fiscal control of the construction and renovation process.
|November 19, 2015|
|08:32 EDT||AEZS||Aeterna Zentaris enrolls first patient for Phase 3 trial of Macrilen|
Aeterna Zentaris has enrolled the first patient for its confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. Based on meetings with the FDA as well as the EMA and subsequent written scientific advice, the company believes that the study meets the FDA's and the EMA's study-design expectations allowing US and European approval, if successful.
|November 18, 2015|
|08:34 EDT||AEZS||Aeterna Zentaris announces share consolidation details for NASDAQ compliance|
Subscribe for More Information
|November 17, 2015|
|06:26 EDT||MDAS||The Advisory Board initiated with an Overweight at JPMorgan|
Subscribe for More Information